News

Filament BioSolutions, a development-stage company focused on delivering innovative therapeutics for nutritional deficiencies, announced continued progress in the development of its…
Read More...

Catalent Pharma Solutions and Berkeley Lights announced Catalent Biologics will adopt BLI’s Beacon optofluidic platform to accelerate its cell line development workflow. The Beacon…
Read More...

Selexis SA announced that under the terms of an earlier commercial license agreement, Symphogen A/S has opened two investigational new drug applications (INDs) for clinical programs…
Read More...

SRI International announced a research agreement with Ionis Pharmaceuticals, combining SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis'…
Read More...

BioCryst Pharmaceuticals announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals following the BioCryst stockholders’ failure to approve…
Read More...

ProBioGen AG and Pionyr Immunotherapeutics announced a second service and license agreement to develop novel antibody therapeutics. Under the terms of the agreement, ProBioGen will…
Read More...

International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced that its…
Read More...

BioIVT announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems…
Read More...

Teva Pharmaceutical Industries  announced the launch of a generic version of Uceris1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are…
Read More...

Herantis Pharma Plc announced the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson’s disease and potentially other neurodegenerative…
Read More...

Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of…
Read More...

Mylan announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon Patch. Mylan received final…
Read More...

MabVax Therapeutics Holdings and Boehringer Ingelheim announced they have signed an asset acquisition and related agreements centered on MabVax's program targeting a glycan commonly…
Read More...

TRIGR Therapeutics, a US-based Biopharmaceutical company, and ABL Bio Corporation, a South Korean biotechnology company, jointly announced that it had entered into a binding agreement…
Read More...

Acceleron Pharma announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr. Zeldin brings to Acceleron more than two decades of clinical, regulatory and…
Read More...

Jazz Pharmaceuticals announced a definitive agreement to sell its rights related to Prialt (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in…
Read More...

Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer and other diseases, today announced the…
Read More...

Belgium-based global bio-pharmaceutical company UCB announced it has received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA), creating a pathway to make…
Read More...

Eisai Co., Ltd and Biogen Inc announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's…
Read More...

Sorrento Therapeutics announced that it acquired the Sofusa lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, particularly, the…
Read More...